MACROGENICS, INC. Proceeds from Issuance or Sale of Equity
MACROGENICS, INC. (MGNX) reported Proceeds from Issuance or Sale of Equity of $141.00 million for the 1-month period ending 2015-07-31, per its 10-K filed 2018-02-27.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2018-02-27
- 2015-07-31: Proceeds from Issuance or Sale of Equity 1 month $141.00M.
- 2014-02-28: Proceeds from Issuance or Sale of Equity 1 month $76.70M.
| Period end | Proceeds from Issuance or Sale of Equity 1 month |
|---|---|
| 2015-07-31 | $141.00M 10-K · filed 2018-02-27 |
| 2014-02-28 | $76.70M 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |